MDCO Overview
Upcoming Projects (MDCO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MDCO)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (MDCO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MDCO)
-
Data from The Medicines Company's(MDCO) Phase 2 ORION 3 study of Inclisiran in Cardiovascular disease (ASCVD) Released
Ticker: MDCO
Occurred on: May 18, 2019 -
Initial data from the ORION-1 Phase 2 study on ALN-PCSsc are expected to be presented by The Medicines Company (MDCO) on November 15, 2016
Tickers: ALNY, MDCO
Occurred on: Nov 15, 2016 -
Medicines Company (MDCO) Announces 90-Day Interim Results from Phase 2 ORION-1 Evaluating PCSK9si in Reducing Cholesterol
Ticker: MDCO
Occurred on: Oct 18, 2016 -
The Medicines Company (MDCO) Announces $132MM Government Contract to Develop Antibiotics for Drug-Resistant Gram-Negative Infections
Ticker: MDCO
Occurred on: Sep 21, 2016 -
The Medicines Company Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE
Ticker: MDCO
Occurred on: Jun 27, 2016 -
The Medicines Company Announces Initiation of Phase II Study for its Investigational Anesthetic, ABP-700
Ticker: MDCO
Occurred on: Jun 14, 2016
Strategic Initiatives (MDCO)
-
Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy
Tickers: NVS, ARWR, MDCO
Announcement Date: Nov 24, 2019
